Woodlands-based MolecularHealth has announced that it has recruited three new members for its U.S. sales team to fill the positions of regional vice president and senior account directors. The hiring is a result of the company’s recent growth, due to the launch of its personalized TreatmentMAP technology for cancer patients, which debuted in April and has already experienced success in the cancer treatment marketplace.
All of the three new additions to the sales team have proven backgrounds in pharmaceutical and diagnostics sales, and are all former employees of Life Technologies. “As our business continues to grow, there are clear indicators that a larger sales presence in the U.S. is needed,” said Chet Dye, senior vice president and chief development officer at MolecularHealth.
Matt Brunner was chosen to serve as regional vice president for the Western region, and with 15 years of experience in sales, mainly within the oncology field, he will work closely with Dye. Bruce Mrachek and Lee Stuart are two other new additions to the sales team, and they will serve as senior account directors for the Southwest and Southeast regions, respectively.
“These new additions to the team reflect the great traction we are seeing since the recent launch of TreatmentMAP. With the demand for MolecularHealth’s services increasing, we want to ensure our team is fully staffed with individuals highly capable of delivering the best experiences to physicians and patients,” said Dye. “The collective and individual experiences of Matt, Bruce and Lee in oncology, diagnostics and pharma bring additional value to our already-stellar sales team.”
Due to the success of its novel services, the company had already engaged in some key staff additions in recent months. At the beginning of July, the company announced the nomination of Gabriel Bien-Willner, M.D., Ph.D., as the new medical director of its CLIA-certified next-generation sequencing lab in the Woodlands, Texas. Previously in March, it announced the addition of Armin Weinberg, Ph.D., Leonard Kalman, M.D., and Michael Kolodziej, M.D., to the company’s advisory board in order to accelerate the launch of TreatmentMAP.
TreatmentMAP, launched by MolecularHealth in March, is a laboratory-developed test performed at MolecularHealth’s CLIA-certified laboratory that transforms molecular data into clinically actionable information in order to enable physicians to do more efficient and safer cancer treatment options for each individual cancer patient. After more than eight years in development by a multidisciplinary team of doctors, scientists and IT experts, as well as collaboration from the University of Texas MD Anderson Cancer Center, MolecularHealth’s system is currently available in both the United States and Europe.